+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2025

  • PDF Icon

    Report

  • 200 Pages
  • April 2025
  • Region: Global
  • The Business Research Company
  • ID: 5988353
This Prostate Cancer Nuclear Medicine Diagnostics market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The prostate cancer nuclear medicine diagnostics market size has grown rapidly in recent years. It will grow from $0.86 billion in 2024 to $0.99 billion in 2025 at a compound annual growth rate (CAGR) of 15%. The growth in the historic period can be attributed to increasing demand for pet scans, increasing urbanization, rise in disposable income, rise in need for accurate cancer diagnosis, increasing emphasis on early detection.

The prostate cancer nuclear medicine diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.71 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth in the forecast period can be attributed to rising prevalence of prostate cancer, increasing demand for positron emission tomography, rising awareness about environmental sustainability, rising frequency of cancers, increasing digital transformation. Major trends in the forecast period include product innovation, technological advancements, advancements in nuclear medicine imaging, improved radiopharmaceuticals and imaging methods, innovative radiopharmaceuticals.

The increasing prevalence of prostate cancer is expected to drive the growth of the prostate cancer nuclear medicine diagnostics market. Prostate cancer is a type of cancer that develops in the prostate, a small, walnut-shaped gland in men responsible for producing seminal fluid that nourishes and transports sperm. The rise in prostate cancer cases can be attributed to factors such as an aging population, lifestyle changes, and genetic predisposition. Prostate cancer nuclear medicine diagnostics offer critical insights that allow healthcare providers to deliver more accurate, effective, and tailored treatment for patients with prostate cancer. For example, in February 2024, the World Health Organization, a Switzerland-based agency specializing in global public health, projected that by 2050, there will be over 35 million new cancer cases, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of prostate cancer is driving the market for prostate cancer nuclear medicine diagnostics.

Key players in the prostate cancer nuclear medicine diagnostics sector are actively innovating diagnostic imaging technologies and securing approvals from the US Food and Drug Administration (FDA). FDA clearance ensures healthcare providers and patients have access to safe and effective diagnostic tests for various medical conditions. For example, in March 2022, Novartis, a Swiss pharmaceutical company, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for treating adult patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) that expresses prostate-specific membrane antigen-positive (PSMA-positive). Pluvicto combines a targeting compound (ligand) with a therapeutic radioisotope, delivering precise cancer treatment to prostate cancer cells expressing PSMA.

In March 2023, Life Healthcare Group, a South African healthcare company, acquired TheraMed Nuclear to enhance its diagnostic imaging services, particularly in detecting and treating diseases such as organ dysfunction and cancer. TheraMed Nuclear, based in South Africa, specializes in prostate cancer nuclear medicine diagnostics.

Major companies operating in the prostate cancer nuclear medicine diagnostics market are Cardinal Health, General Electric, Bayer AG, Novartis AG, Siemens Healthineers AG, GE Healthcare, Lantheus, CURIUM PHARMA, Telix Pharmaceuticals Ltd., Eckert & Ziegler AG, Point Biopharma Global Inc., Point Biopharma, Alliance Medical Ltd., SHINE Medical Technologies LLC, PETNET Solution, NorthStar Medical Radioisotopes LLC, Global Medical Solutions LLC, Isotope Technologies Garching (ITG), Jubilant Pharma Limited, Blue Earth Diagnostics Inc., Institute of Isotopes Co. Ltd., Radiopharm Theranostics, Bracco Diagnostic Inc., NCM-USA LLC, ABX Advanced Biochemical Compounds GmbH.

North America was the largest region in the prostrate cancer nuclear medicine diagnostics market in 2024. The regions covered in the prostate cancer nuclear medicine diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the prostate cancer nuclear medicine diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Prostate cancer nuclear medicine diagnostics involve the utilization of radioactive substances to detect and assess prostate cancer. These diagnostics play a crucial role in the detection, staging, and management of prostate cancer by providing comprehensive functional information regarding the disease's extent and characteristics. The process entails introducing radioactive substances (radiopharmaceuticals) into the body, typically through injection, which emit gamma rays or positrons.

The primary types of prostate cancer nuclear medicine diagnostics include single photon emission computed tomography (SPECT) and positron emission tomography (PET). Single photon emission computed tomography (SPECT) is a nuclear imaging technique that generates detailed three-dimensional images depicting the body's functional processes. These diagnostics encompass various test types, including preliminary and confirmatory tests, and are utilized by various end-users such as hospitals, clinics, and others.

The prostate cancer nuclear medicine diagnostics market research report is one of a series of new reports that provides prostate cancer nuclear medicine diagnostics market statistics, including prostate cancer nuclear medicine diagnostics industry global market size, regional shares, competitors with a prostate cancer nuclear medicine diagnostics market share, detailed prostate cancer nuclear medicine diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the prostate cancer nuclear medicine diagnostics industry. This prostate cancer nuclear medicine diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The prostate cancer nuclear medicine diagnostics market includes revenues earned by entities by bone scans, prostate-specific membrane antigen (PSMA) PET scan, bone scintigraphy, and CT scans. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.

Table of Contents

1. Executive Summary2. Prostate Cancer Nuclear Medicine Diagnostics Market Characteristics3. Prostate Cancer Nuclear Medicine Diagnostics Market Trends and Strategies4. Prostate Cancer Nuclear Medicine Diagnostics Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
5. Global Prostate Cancer Nuclear Medicine Diagnostics Growth Analysis and Strategic Analysis Framework
5.1. Global Prostate Cancer Nuclear Medicine Diagnostics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis of End Use Industries
5.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market Growth Rate Analysis
5.4. Global Prostate Cancer Nuclear Medicine Diagnostics Historic Market Size and Growth, 2019-2024, Value ($ Billion)
5.5. Global Prostate Cancer Nuclear Medicine Diagnostics Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
5.6. Global Prostate Cancer Nuclear Medicine Diagnostics Total Addressable Market (TAM)
6. Prostate Cancer Nuclear Medicine Diagnostics Market Segmentation
6.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Single Photon Emission Computed Tomography (SPECT)
  • Photon Emission Computed Tomography (PET)
6.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Preliminary Tests
  • Confirmatory Tests
6.3. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Other End Users
6.4. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation of Single Photon Emission Computed Tomography (SPECT), by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gamma Camera SPECT
  • Hybrid SPECT or CT Imaging
6.5. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Sub-Segmentation of Positron Emission Tomography (PET), by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PET or CT Imaging
  • PET or MRI Imaging
7. Prostate Cancer Nuclear Medicine Diagnostics Market Regional and Country Analysis
7.1. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Prostate Cancer Nuclear Medicine Diagnostics Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market
8.1. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Prostate Cancer Nuclear Medicine Diagnostics Market
9.1. China Prostate Cancer Nuclear Medicine Diagnostics Market Overview
9.2. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Prostate Cancer Nuclear Medicine Diagnostics Market
10.1. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Prostate Cancer Nuclear Medicine Diagnostics Market
11.1. Japan Prostate Cancer Nuclear Medicine Diagnostics Market Overview
11.2. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Prostate Cancer Nuclear Medicine Diagnostics Market
12.1. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market
13.1. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market
14.1. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market Overview
14.2. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market
15.1. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
15.2. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Prostate Cancer Nuclear Medicine Diagnostics Market
16.1. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Prostate Cancer Nuclear Medicine Diagnostics Market
17.1. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Prostate Cancer Nuclear Medicine Diagnostics Market
18.1. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Prostate Cancer Nuclear Medicine Diagnostics Market
19.1. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Prostate Cancer Nuclear Medicine Diagnostics Market
20.1. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market
21.1. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market Overview
21.2. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Prostate Cancer Nuclear Medicine Diagnostics Market
22.1. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Prostate Cancer Nuclear Medicine Diagnostics Market
23.1. North America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
23.2. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Prostate Cancer Nuclear Medicine Diagnostics Market
24.1. USA Prostate Cancer Nuclear Medicine Diagnostics Market Overview
24.2. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Prostate Cancer Nuclear Medicine Diagnostics Market
25.1. Canada Prostate Cancer Nuclear Medicine Diagnostics Market Overview
25.2. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Prostate Cancer Nuclear Medicine Diagnostics Market
26.1. South America Prostate Cancer Nuclear Medicine Diagnostics Market Overview
26.2. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market
27.1. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market
28.1. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market Overview
28.2. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Prostate Cancer Nuclear Medicine Diagnostics Market
29.1. Africa Prostate Cancer Nuclear Medicine Diagnostics Market Overview
29.2. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Prostate Cancer Nuclear Medicine Diagnostics Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape and Company Profiles
30.1. Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Landscape
30.2. Prostate Cancer Nuclear Medicine Diagnostics Market Company Profiles
30.2.1. Cardinal Health Overview, Products and Services, Strategy and Financial Analysis
30.2.2. General Electric Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
31. Prostate Cancer Nuclear Medicine Diagnostics Market Other Major and Innovative Companies
31.1. GE Healthcare
31.2. Lantheus
31.3. CURIUM PHARMA
31.4. Telix Pharmaceuticals Ltd.
31.5. Eckert & Ziegler AG
31.6. Point Biopharma Global Inc.
31.7. Point Biopharma
31.8. Alliance Medical Ltd.
31.9. SHINE Medical Technologies LLC
31.10. PETNET Solution
31.11. NorthStar Medical Radioisotopes LLC
31.12. Global Medical Solutions LLC
31.13. Isotope Technologies Garching (ITG)
31.14. Jubilant Pharma Limited
31.15. Blue Earth Diagnostics Inc.
32. Global Prostate Cancer Nuclear Medicine Diagnostics Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Prostate Cancer Nuclear Medicine Diagnostics Market34. Recent Developments in the Prostate Cancer Nuclear Medicine Diagnostics Market
35. Prostate Cancer Nuclear Medicine Diagnostics Market High Potential Countries, Segments and Strategies
35.1 Prostate Cancer Nuclear Medicine Diagnostics Market in 2029 - Countries Offering Most New Opportunities
35.2 Prostate Cancer Nuclear Medicine Diagnostics Market in 2029 - Segments Offering Most New Opportunities
35.3 Prostate Cancer Nuclear Medicine Diagnostics Market in 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Prostate Cancer Nuclear Medicine Diagnostics Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on prostate cancer nuclear medicine diagnostics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase:

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Description

Where is the largest and fastest growing market for prostate cancer nuclear medicine diagnostics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The prostate cancer nuclear medicine diagnostics market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

1) By Type: Single Photon Emission Computed Tomography (SPECT); Photon Emission Computed Tomography (PET)
2) By Test Type: Preliminary Tests; Confirmatory Tests
3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Single Photon Emission Computed Tomography (SPECT): Gamma Camera SPECT; Hybrid SPECT or CT Imaging
2) By Positron Emission Tomography (PET): PET or CT Imaging; PET or MRI Imaging

Key Companies Mentioned: Cardinal Health; General Electric; Bayer AG; Novartis AG; Siemens Healthineers AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery Format: PDF, Word and Excel Data Dashboard.

Companies Mentioned

The major companies featured in this Prostate Cancer Nuclear Medicine Diagnostics market report include:
  • Cardinal Health
  • General Electric
  • Bayer AG
  • Novartis AG
  • Siemens Healthineers AG
  • GE Healthcare
  • Lantheus
  • CURIUM PHARMA
  • Telix Pharmaceuticals Ltd.
  • Eckert & Ziegler AG
  • Point Biopharma Global Inc.
  • Point Biopharma
  • Alliance Medical Ltd.
  • SHINE Medical Technologies LLC
  • PETNET Solution
  • NorthStar Medical Radioisotopes LLC
  • Global Medical Solutions LLC
  • Isotope Technologies Garching (ITG)
  • Jubilant Pharma Limited
  • Blue Earth Diagnostics Inc.
  • Institute of Isotopes Co. Ltd.
  • Radiopharm Theranostics
  • Bracco Diagnostic Inc.
  • NCM-USA LLC
  • ABX Advanced Biochemical Compounds GmbH

Table Information